Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...

AlphaFold, a transformative AI-driven tool developed by DeepMind, has revolutionized the field of structural biology by accurately predicting protein structures. This breakthrough holds significant ...

VivaMed BioPharma (VivaMed), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to discover and advance repurposed and improved therapeutic assets, today announced a ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Explore the role of BD&L in R&D decision-making. Understand its impact on funding and market intelligence for scientists.

Creating a drug that might help treat or cure a health condition in humans is a long, complex process. After developing a ...

The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...

The Mark Foundation for Cancer Research today announced four recipients of the 2026 Drug Discovery Awards, a program designed to bridge the gap between academic discovery and clinical application.

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.

Lario secures $2.4 million in funding to advance drug discovery for neurological disorders and transform precision medicine.